Zentalis Pharmaceuticals ... (ZNTL)
2.77
0.13 (4.73%)
At close: Jan 15, 2025, 12:47 PM
undefined% (undefined)
| Bid | 2.76 |
| Market Cap | 197.41M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.5 |
| PE Ratio (ttm) | -1.11 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.77 |
| Volume | 812,082 |
| Avg. Volume (20D) | 1,330,350 |
| Open | 2.77 |
| Previous Close | 2.65 |
| Day's Range | 2.71 - 2.88 |
| 52-Week Range | 2.41 - 18.07 |
| Beta | undefined |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 3, 2020
Employees 124
Stock Exchange NASDAQ
Ticker Symbol ZNTL
Website https://zentalis.com
Analyst Forecast
According to 8 analyst ratings, the average rating for ZNTL stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 206.86% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
Zentalis Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025,
before market opens.
Analysts project revenue of $36.16M, reflecting a n/a YoY growth and earnings per share of -3, making a 294.74% increase YoY.
Analysts project revenue of $36.16M, reflecting a n/a YoY growth and earnings per share of -3, making a 294.74% increase YoY.
5 days ago ·
Source
-1.08%
Zentalis Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
2 months ago ·
Source
-12.15%
Zentalis Pharmaceuticals shares are trading lower after Guggenheim cut its price target on the stock from $12 to $8.
